This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More
Category: News
Patient survey on THC:CBD in people with ALS
The THC:CBD patient survey is a systematic survey of 130 patients with amyotrophic lateral sclerosis (ALS), in which important findings on experience and satisfaction with treatment with cannabis-containing medicines containing tetrahydrocannabinol (THC) and cannabidiol (CBD) are obtained. Cannabis-containing treatment for ALS Medicines containing cannabis are used for severe illnesses when conventional medicines are not sufficiently…
New medication module in the outpatient partner care portal
We are pleased to inform you that we have completely revised our medication module. With the new version, we want to make the medication supply processes more transparent, efficient and clearer. It went live in the Ambulanzpartner care portal on September 22, 2025. The old and new medication modules will be available in parallel in…
Redeem your e-prescription in the ALS app at your ALS pharmacy and continue to support ALS research
You can now redeem your e-prescription with your health card via the ALS app at your specialist ALS pharmacy! You can also continue to be supplied via your ALS pharmacy with the e-prescription and take part in ALS research. Have four things ready: Electronic health card. You will find the 6-digit CAN number (“Card Access…
Patient survey on eye control glasses for people with ALS
The patient survey on eye control glasses is a nationwide, systematic survey of patients with amyotrophic lateral sclerosis (ALS). The aim of the survey is to gain important insights into expectations of the eye-control glasses as well as experiences and satisfaction following treatment with the innovative aid. Drive the wheelchair safely with eye control glasses…
The individual progression of ALS in the ALS app: the new “My progression form” function
The course of ALS (amyotrophic lateral sclerosis) can be very different and individual. The way in which the symptoms develop is described by the specific progression that is present in each affected person. Two factors are particularly important for an individual assessment of the course of the disease: To be able to better assess the course…
Update of the SMA app: new functions and improved user-friendliness
We have added some new functions to the SMA app and improved its user-friendliness. The latest update of the SMA app (version 2.0.3) is available to download free of charge from the Apple App Store and Google Play. We would like to briefly introduce you to the changes in the current version. Self-assessment of the…
Study on the treatment of people with 5q-SMA with nusinersen in adulthood
Treatment with the drug nusinersen is available for people with 5q-associated spinal muscular atrophy (5q-SMA). In our application study with people with 5q-SMA who received nusinersen therapy in adulthood, the treatment goals, symptom progression and treatment satisfaction with the drug were systematically investigated. In the period from July 2019 to September 2020, Ambulanzpartner conducted an…
Digital care during the coronavirus pandemic: communicating requirements for medical aids and medication online
The reliable supply of aids and medication is crucial for people with amyotrophic lateral sclerosis (ALS) and other neuromuscular diseases. At the same time, transportation and travel restrictions during the coronavirus pandemic can make it more difficult to provide outpatient care. To ensure outpatient care, Ambulanzpartner offers patients the opportunity to document their care needs…
The SMA app during the coronavirus pandemic: support for adults with SMA and doctors
The corona pandemic necessitates infection control measures that are associated with a significant change in the care and treatment of people with spinal muscular atrophy (SMA). In this situation, telemedical visits between doctors and patients take on a previously unknown significance. Digital recording of SMA symptoms During a telemedical visit, the systematic communication of symptoms…